Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS study ...
I heard there will be a saliva test to see who has a high risk of getting prostate cancer. I don’ t see how saliva would have anything to do with your prostate gland. How does the test work, and how ...